NEW YORK (360Dx) – Clearbridge Health Limited said today that it has entered into an exclusive partnership with Hunan, China's Agen Medicine Laboratory Technology Company, under which it will provide the firm with its ClearCell FX1 System for circulating tumor cell enrichment, offer training and assistance in Agen's development of laboratory developed tests, and then market those tests in China.
Financial terms of the deal were not disclosed.
ClearCell FX1, which was designed and manufactured by Singapore-based Clearbridge BioMedics, is an automated system for isolating and enriching wholly intact, viable CTCs from blood.
Clearbridge Executive Director and CEO Jeremy Yee said in a statement that the company believes this new collaboration will result in its platform being incorporated into a "suite of LDTs" to support more accurate, broader cancer diagnosis and treatment.